Changchun High-Tech Industry (Group) (000661) Q4 2024 earnings summary

Executive summary

• Revenue for 2024 was ¥13.47 billion, down 7.55% year-over-year; net profit attributable to shareholders was ¥2.58 billion, down 43.01% year-over-year.

• Main business includes biopharmaceuticals, traditional Chinese medicine, and real estate, with biopharma accounting for 94% of revenue.

• R&D investment increased 11.20% to ¥2.69 billion, representing 19.97% of revenue.

• Major subsidiaries: Jinsai Pharma, Baike Bio, Huakang Pharma, and Gaoxin Real Estate.

Financial highlights

• Operating income: ¥13.47 billion (down 7.55% YoY); net profit: ¥2.58 billion (down 43.01% YoY).

• Operating cash flow: ¥3.10 billion (down 39.18% YoY).

• Basic and diluted EPS: ¥6.42 (down 42.73% and 41.95% YoY, respectively).

• Gross margin for biopharma: 89.44%; for gene engineering/biological drugs: 91.10%.

• Total assets: ¥31.05 billion (up 1.00% YoY); net assets attributable to shareholders: ¥22.99 billion (up 4.19% YoY).

Outlook and guidance

• Focus on innovation, compliance, and internationalization; continue to invest in R&D and expand product pipeline.

• Plans to optimize real estate business, accelerate inventory clearance, and improve capital efficiency.

• Emphasis on cost control, digital transformation, and asset utilization to enhance profitability.